Evidence-based insights into peptide protocols, safety research, and optimization strategies. Built on clinical rigor, powered by community knowledge.
Get weekly insights on peptide protocols, safety updates, and optimization strategies delivered to your inbox.
No spam. Unsubscribe anytime. Clinical rigor, always.
Deep dives into peptide science — evidence-graded, honestly reported
HPTA recovery after testosterone therapy takes far longer than forums claim. Established PCT has limits, and peptides offer a mechanistically compelling but clinically unproven layer on top.
Exogenous testosterone suppresses the hypothalamic-pituitary-testicular axis at every level. Recovery is measured in months to years, not weeks. This article maps the clinical timeline, examines where Kisspeptin-10, triptorelin, and GH secretagogues fit, and is honest about what the evidence does and does not support.
Evidence-graded testosterone profiles by ester and formulation, with safety data and peptide alternatives
The same TRT protocol becomes a fundamentally different risk proposition at 30 than at 50. Here's where the calculus shifts, and where peptides start winning specific trades.
After 35, cardiovascular remodeling accelerates, prostate risk compounds, and HPTA recovery narrows. This article maps the age-stratified risk data for TRT and identifies where GH secretagogues, the Wolverine Stack, and Sermorelin offer lower-cost alternatives for specific outcomes.
The most prescribed testosterone ester outside the US, with a 4.5-7 day half-life that demands weekly dosing for stable levels. What the clinical data says about the hepcidin hijack, erythrocytosis, and why dosing frequency matters more than dose size.
Evidence-graded profile of testosterone enanthate: the hepcidin mechanism behind erythrocytosis, DHT and the scrotal paradox, dosing frequency pharmacokinetics, the TRAVERSE prostate saturation model, age-stratified risk, and peptide alternatives.
35+
Articles
18
Categories